Esthesioneuroblastoma : mansoura university hospitals’ experience with multimodality therapy in 10 years

Background : Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare and aggressive malignant tumour of the nasal cavity and paranasal sinuses. This study was conducted to evaluate and analyse the outcomes of the combined modality regimen including surgery, radiotherapy and che...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Egyptian journal of ear, nose, throat and allied sciences nose, throat and allied sciences, 2013, Vol.14 (1), p.17-22
Hauptverfasser: Kamal, al-Sharawi, Abd al-Fattah, Ahmad Masad, Imam, Hazim, Qasim, Muhammad, al-Ashri, Muhammad, Abd al-Wahhab, Abd al-Wahhab M., Tawfiq, Ali
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background : Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare and aggressive malignant tumour of the nasal cavity and paranasal sinuses. This study was conducted to evaluate and analyse the outcomes of the combined modality regimen including surgery, radiotherapy and chemotherapy. Methods : From January 2001 to January 2012 ; in a retrospective analysis ; 10 patients with ENB were treated in Mansoura University Hospitals at the Otolaryngology Department. Four patients were of Kadish stage B and six were of stage C. In four cases of stage C, invasion of the anterior cranial fossa was detected. No patient had lymph nodes or distant metastases. All patients received a combined multimodality treatment including surgery ; craniofacial or endoscopic resections ; radiotherapy and combined vepesid and cisplatin chemotherapy. Results : Nine patients, over an average follow-up which ranged from 5 to 8 years (mean 6.2 ; SD 3.01), are actually alive with no evidence of disease in eight patients and locoregional recurrence in one patient who underwent salvage therapy.
ISSN:2090-0740
2090-3405